Related Experiment Videos
Ceftriaxone therapy in pediatric patients
Insights
Ceftriaxone sodium effectively treated bacterial infections in most children, with clinical and microbiologic cures in 19 of 21 patients. While generally safe, some experienced mild side effects like diarrhea and candidiasis.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Bacterial infections pose a significant threat to pediatric health.
- Intravenous antibiotics are crucial for treating severe pediatric infections.
- Ceftriaxone is a broad-spectrum cephalosporin antibiotic used in children.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous ceftriaxone sodium in pediatric patients.
- To assess clinical and microbiologic outcomes in children treated with ceftriaxone.
- To identify and document adverse events associated with ceftriaxone therapy in children.
Main Methods:
- A cohort of 26 children (2 months to 15 years) received intravenous ceftriaxone sodium (37.5 mg/kg every 12 hours) for an average of seven days.
- Clinical and microbiologic assessments were performed to determine treatment outcomes.
- Adverse events and laboratory abnormalities were monitored throughout the study.
Main Results:
- Clinical and microbiologic cures were achieved in 19 out of 21 patients with culturable bacterial pathogens.
- Ceftriaxone was ineffective in one case of Staphylococcus aureus periorbital cellulitis and a Salmonella meningitis relapse occurred.
- Common side effects included transient diarrhea (11 patients), superficial candidiasis (10 patients), and asymptomatic laboratory abnormalities (15 patients).
Conclusions:
- Intravenous ceftriaxone sodium demonstrates significant efficacy in treating bacterial infections in pediatric patients.
- The antibiotic is generally well-tolerated, with most adverse events being mild and transient.
- Ceftriaxone is a viable treatment option for pediatric bacterial infections, though resistance and specific cases require careful consideration.
Abstract:
Twenty-six children, aged 2 months to 15 years, were treated with intravenous ceftriaxone sodium, 37.5 mg/kg every 12 hours, for an average of seven days. Clinical and microbiologic cures occurred in 19 of 21 patients, from whom bacterial pathogens were cultured. Ceftriaxone was not effective in treating an 18-month-old infant with periorbital cellulitis caused by relatively resistant Staphylococcus aureus. A relapse occurred in a 2-month-old infant with meningitis caused by ceftriaxone-sensitive Salmonella. Eleven patients had transient diarrhea, superficial candidiasis developed in ten patients, and one patient experienced skin flushing during administration of the antibiotic. Transient asymptomatic laboratory abnormalities were detected in 15 patients; nine patients had elevated serum concentrations of transaminases or bilirubin, 11 had thrombocytosis, three experienced eosinophilia, and one had thrombocytopenia. Transient suppression of normal flora of the intestine occurred in 21 patients. Side effects were not serious enough to warrant discontinuing ceftriaxone therapy in any patient.